Systematic review: Histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative

Journal of Crohn's and Colitis

Volumn 8, Issue 12, 2014, Pages 1582-1597

  Bryant, R V ^a   Winer, S ^b   SPL, Travis ^a   Riddell, R H ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Histological healing; Histological indices; Histology; Inflammatory bowel disease; Mucosal healing; Ulcerative colitis

Indexed keywords

CLINICAL TRIAL (TOPIC); GASTROINTESTINAL ENDOSCOPY; HUMAN; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; PATHOLOGY; PROGNOSIS; REMISSION; WOUND HEALING;

CLINICAL TRIALS AS TOPIC; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; PROGNOSIS; REMISSION INDUCTION; WOUND HEALING;

EID: 84918817166     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.08.011     Document Type: Review

References (121)

1. D'Haens G., Sandborn W.J., Feagan B.G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology Feb 2007, 132(2):763-786. [PubMed PMID: 17258735. Epub 2007/01/30. eng].
2. Travis S.P., Higgins P.D., Orchard T., et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther Jul 2011, 34(2):113-124. [PubMed PMID: 21615435. Epub 2011/05/28. eng].
3. Daperno M., Castiglione F., de Ridder L., et al. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis Oct 2011, 5(5):484-498. [PubMed PMID: 21939926. Epub 2011/09/24. eng].
4. Peyrin-Biroulet L., Ferrante M., Magro F., et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis Oct 2011, 5(5):477-483. [PubMed PMID: 21939925. Epub 2011/09/24. eng].
5. Stange E.F., Travis S.P., Vermeire S., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut Mar 2006, 55(Suppl. 1):i1-i15. [PubMed PMID: 16481628. Pubmed Central PMCID: 1859998. Epub 2006/02/17. eng].
6. Stange E.F., Travis S.P., Vermeire S., et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis Mar 2008, 2(1):1-23. [PubMed PMID: 21172194. Epub 2008/03/01. eng].
7. Reinisch W., Van Assche G., Befrits R., et al. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis Mar 2012, 6(2):248-258. [PubMed PMID: 22325181. Epub 2012/02/14. eng].
8. Ardizzone S., Cassinotti A., Duca P., et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol Jun 2011, 9(6):483-489. [e3. PubMed PMID: 21195796. Epub 2011/01/05. eng].
9. Froslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology Aug 2007, 133(2):412-422. [PubMed PMID: 17681162. Epub 2007/08/08. eng].
10. Colombel J.F., Rutgeerts P., Reinisch W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology Oct 2011, 141(4):1194-1201. [PubMed PMID: 21723220. Epub 2011/07/05. eng].
11. Baert F., Moortgat L., Van Assche G., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology Feb 2010, 138(2):463-468. [quiz e10-1. PubMed PMID: 19818785. Epub 2009/10/13. eng].
12. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet Feb 23 2008, 371(9613):660-667. [PubMed PMID: 18295023. Epub 2008/02/26. eng].
13. Rutgeerts P., Diamond R.H., Bala M., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc Mar 2006, 63(3):433-442. [quiz 64. PubMed PMID: 16500392. Epub 2006/02/28. eng].
14. Schnitzler F., Fidder H., Ferrante M., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis Sep 2009, 15(9):1295-1301. [PubMed PMID: 19340881. Epub 2009/04/03. eng].
15. De Cruz P., Kamm M.A., Prideaux L., et al. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis Feb 2013, 19(2):429-444. [PubMed PMID: 22539420. Epub 2012/04/28. eng].
16. Neurath M.F., Travis S.P. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut Nov 2012, 61(11):1619-1635. [PubMed PMID: 22842618. Epub 2012/07/31. eng].
17. Korelitz B.I. Mucosal healing as an index of colitis activity: back to histological healing for future indices. Inflamm Bowel Dis Sep 2010, 16(9):1628-1630. [PubMed PMID: 20803700. Epub 2010/08/31. eng].
18. Riley S.A., Mani V., Goodman M.J., et al. Microscopic activity in ulcerative colitis: what does it mean?. Gut Feb 1991, 32(2):174-178. [PubMed PMID: 1864537. Pubmed Central PMCID: 1378803. Epub 1991/02/01. eng].
19. Rosenberg L., Nanda K.S., Zenlea T., et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol Aug 2013, 11(8):991-996. [PubMed PMID: 23591275. Pubmed Central PMCID: PMC3753658. Epub 2013/04/18. eng].
20. Azad S., Sood N., Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol May Jun 2011, 17(3):194-198. [PubMed PMID: 21546723. Pubmed Central PMCID: 3122090. Epub 2011/05/07. eng].
21. Bitton A., Peppercorn M.A., Antonioli D.A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology Jan 2001, 120(1):13-20. [PubMed PMID: 11208709. Epub 2001/02/24. eng].
22. Gupta R.B., Harpaz N., Itzkowitz S., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology Oct 2007, 133(4):1099-1105. [quiz 340-1. PubMed PMID: 17919486. Pubmed Central PMCID: PMC2175077. Epub 2007/10/09. eng].
23. Wright R., Truelove S.R. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis Nov 1966, 11(11):847-857. [PubMed PMID: 5953695. Epub 1966/11/01. eng].
24. Bessissow T., Lemmens B., Ferrante M., et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol Nov 2012, 107(11):1684-1692. [PubMed PMID: 23147523. Epub 2012/11/14. eng].
25. Hefti M.M., Chessin D.B., Harpaz N.H., et al. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum Feb 2009, 52(2):193-197. [PubMed PMID: 19279411. Pubmed Central PMCID: PMC2753491. Epub 2009/03/13. eng].
26. Rubin DT H.D., Hetzel J.T., et al. Increased degree of histological inflammation predicts colectomy and hospitalisation in patients with ulcerative colitis. Gut 2007, 132(Suppl. 1):A-19. (Abstract 103).
27. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology Feb 2004, 126(2):451-459. [PubMed PMID: 14762782. Epub 2004/02/06. eng].
28. D'Haens G.R., Fedorak R., Lemann M., et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis Oct 2009, 15(10):1599-1604. [PubMed PMID: 19653291. Epub 2009/08/05. eng].
29. Truelove S.C., Hambling M.H. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial. Br Med J Nov 1 1958, 2(5104):1072-1077. [PubMed PMID: 13584853. Pubmed Central PMCID: 2026833. Epub 1958/11/01. eng].
30. Azad Khan A.K., Piris J., Truelove S.C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet Oct 29 1977, 2(8044):892-895. [PubMed PMID: 72239. Epub 1977/10/29. eng].
31. Goldman H., Antonioli D.A. Mucosal biopsy of the rectum, colon, and distal ileum. Hum Pathol Nov 1982, 13(11):981-1012. [PubMed PMID: 6759364. Epub 1982/11/01. eng].
32. Magro F., Langner C., Driessen A., et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013, 7(10):827-851. [PubMed PMID: 23870728. Epub 2013/07/23. Eng].
33. Langner C., Magro F., Driessen A., et al. The histopathological approach to inflammatory bowel disease: a practice guide. Virchows Arch 2014, 464(5):511-527. [PubMed PMID: 24487791. Epub 2014/02/04. Eng].
34. Seldenrijk C.A., Morson B.C., Meuwissen S.G., et al. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. Gut Dec 1991, 32(12):1514-1520. [PubMed PMID: 1773958. Pubmed Central PMCID: 1379253. Epub 1991/12/01. eng].
35. Surawicz C.M., Haggitt R.C., Husseman M., et al. Mucosal biopsy diagnosis of colitis: acute self-limited colitis and idiopathic inflammatory bowel disease. Gastroenterology Sep 1994, 107(3):755-763. [PubMed PMID: 8076762. Epub 1994/09/01. eng].
36. Simillis C., Jacovides M., Reese G.E., et al. Meta-analysis of the role of granulomas in the recurrence of Crohn disease. Dis Colon Rectum Feb 2010, 53(2):177-185. [PubMed PMID: 20087093. Epub 2010/01/21. eng].
37. Henderson P., van Limbergen J.E., Schwarze J., et al. Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease. Inflamm Bowel Dis Jan 2011, 17(1):382-395. [PubMed PMID: 20645321. Epub 2010/07/21. eng].
38. Sturm A., Dignass A.U. Epithelial restitution and wound healing in inflammatory bowel disease. World J Gastroenterol Jan 21 2008, 14(3):348-353. [PubMed PMID: 18200658. Pubmed Central PMCID: PMC2679124. Epub 2008/01/18. eng].
39. Panaccione R., Colombel J.F., Louis E., et al. Evolving definitions of remission in Crohn's disease. Inflamm Bowel Dis Jul 2013, 19(8):1645-1653. [PubMed PMID: 23598817. Epub 2013/04/20. eng].
40. Peyrin-Biroulet L., Bressenot A., Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis?. Clin Gastroenterol Hepatol 2014, 12(6):929-934. [PubMed PMID: 23911875. Epub 2013/08/06. Eng].
41. Villanacci V., Antonelli E., Geboes K., et al. Histological healing in inflammatory bowel disease: a still unfulfilled promise. World J Gastroenterol Feb 21 2013, 19(7):968-978. [PubMed PMID: 23467585. Pubmed Central PMCID: 3582008. Epub 2013/03/08. eng].
42. Freeman H.J. Limitations in assessment of mucosal healing in inflammatory bowel disease. World J Gastroenterol Jan 7 2010, 16(1):15-20. [PubMed PMID: 20039444. Pubmed Central PMCID: PMC2799912. Epub 2009/12/30. eng].
43. Mazzuoli S., Guglielmi F.W., Antonelli E., et al. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis 2013, 45(12):969-977. [PubMed PMID: 23932331. Epub 2013/08/13. Eng].
44. Mosli M.H., Feagan B.G., Sandborn W.J., et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis Mar 2014, 20(3):564-575. [PubMed PMID: 24412993. Epub 2014/01/15. eng].
45. Hartmann F., Stein J. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther Aug 2010, 32(3):368-376. [PubMed PMID: 20491741. Epub 2010/05/25. eng].
46. Marshall J.K., Thabane M., Steinhart A.H., et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010, 1:CD004115. [PubMed PMID: 20091560. Epub 2010/01/22. eng].
47. Colombel J.F., Rutgeerts P.J., Sandborn W.J., et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014, 12(3):414-422. [PubMed PMID: 23856361. Epub 2013/07/17. Eng].
48. Molander P., Sipponen T., Kemppainen H., et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha-blocking agents in IBD. J Crohns Colitis Oct 1 2013, 7(9):730-735. [PubMed PMID: 23182163. Epub 2012/11/28. eng].
49. Floren C.H., Benoni C., Willen R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol May 1987, 22(4):459-462. [PubMed PMID: 3602926. Epub 1987/05/01. eng].
50. Geboes K., Riddell R., Ost A., et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut Sep 2000, 47(3):404-409. [PubMed PMID: 10940279. Pubmed Central PMCID: 1728046. Epub 2000/08/15. eng].
51. Gomes P., du Boulay C., Smith C.L., et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut Jan 1986, 27(1):92-95. [PubMed PMID: 3949241. Pubmed Central PMCID: 1433178. Epub 1986/01/01. eng].
52. Hanauer S., Schwartz J., Robinson M., et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol Aug 1993, 88(8):1188-1197. [PubMed PMID: 8338086. Epub 1993/08/01. eng].
53. Hanauer S.B., Robinson M., Pruitt R., et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology Sep 1998, 115(3):525-532. [PubMed PMID: 9721148. Epub 1998/08/28. eng].
54. Korelitz B.I., Sommers S.C. Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and mucosal cell counts. Am J Dig Dis Jun 1976, 21(6):441-447. [PubMed PMID: 8981. Epub 1976/06/01. eng].
55. Powell-Tuck J., Day D.W., Buckell N.A., et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci Jun 1982, 27(6):533-537. [PubMed PMID: 6979471. Epub 1982/06/01. eng].
56. Truelove S.C., Richards W.C. Biopsy studies in ulcerative colitis. Br Med J Jun 9 1956, 1(4979):1315-1318. [PubMed PMID: 13316140. Pubmed Central PMCID: 1980058. Epub 1956/06/09. eng].
57. D'Haens G.R., Geboes K., Peeters M., et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology Feb 1998, 114(2):262-267. [PubMed PMID: 9453485. Epub 1998/02/07. eng].
58. Palnaes Hansen C.H.J., Moller A., et al. Ulcerative colitis and Crohn's disease of the colon. Is there a macroscopic difference?. Ann Chir Gynaecol 1990, 79:78-81.
59. Schaeffer D.F., Win L.L., Hafezi-Bakhtiari S., et al. The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis. Dig Dis Sci Sep 2013, 58(9):2608-2614. [PubMed PMID: 23670229. Epub 2013/05/15. eng].
60. Saverymuttu S.H., Camilleri M., Rees H., et al. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology May 1986, 90(5 Pt 1):1121-1128. [PubMed PMID: 3956932. Epub 1986/05/01. eng].
61. Friedman L.S., Richter J.M., Kirkham S.E., et al. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. Am J Gastroenterol Jun 1986, 81(6):412-418. [PubMed PMID: 3518408. Epub 1986/06/01. eng].
62. Keren D.F., Appelman H.D., Dobbins W.O., et al. Correlation of histopathologic evidence of disease activity with the presence of immunoglobulin-containing cells in the colons of patients with inflammatory bowel disease. Hum Pathol Aug 1984, 15(8):757-763. [PubMed PMID: 6378760. Epub 1984/08/01. eng].
63. Matts S.G. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med Oct 1961, 30:393-407. [PubMed PMID: 14471445. Epub 1961/10/01. eng].
64. Sandborn W.J., Tremaine W.J., Schroeder K.W., et al. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol May 1993, 88(5):640-645. [PubMed PMID: 8480724. Epub 1993/05/01. eng].
65. Watts J.M., Thompson H., Goligher J.C. Sigmoidoscopy and cytology in the detection of microscopic disease of the rectal mucosa in ulcerative colitis. Gut Jun 1966, 7(3):288-294. [PubMed PMID: 18668808. Pubmed Central PMCID: 1552413. Epub 1966/06/01. eng].
66. Baars J.E., Nuij V.J., Oldenburg B., et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis Sep 2012, 18(9):1634-1640. [PubMed PMID: 22069022. Epub 2011/11/10. eng].
67. Fiel M.Q.L., Suriawinita A., et al. Histologic grading of disease activity in chronic IBD: inter- and intra-observer variation amongst pathologists with different levels of experience. Mod Pathol 2003, 16:118A.
68. Breese E.J., Michie C.A., Nicholls S.W., et al. The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn's disease. Aliment Pharmacol Ther Oct 1995, 9(5):547-552. [PubMed PMID: 8580276. Epub 1995/10/01. eng].
69. Nicholls S., Domizio P., Williams C.B., et al. Cyclosporin as initial treatment for Crohn's disease. Arch Dis Child Sep 1994, 71(3):243-247. [PubMed PMID: 7979499. Pubmed Central PMCID: 1029980. Epub 1994/09/01. eng].
70. D'Haens G., Van Deventer S., Van Hogezand R., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology May 1999, 116(5):1029-1034. [PubMed PMID: 10220494. Epub 1999/04/30. eng].
71. Geboes K., Rutgeerts P., Opdenakker G., et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin Nov 2005, 21(11):1741-1754. [PubMed PMID: 16307694. Epub 2005/11/26. eng].
72. Travis S.P., Schnell D., Krzeski P., et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013, 145(5):987-995. [PubMed PMID: 23891974. Epub 2013/07/31. Eng].
73. Dick A.P., Grayson M.J. Ulcerative colitis. A follow-up investigation with mucosal biopsy studies. Br Med J Jan 21 1961, 1(5220):160-165. [PubMed PMID: 13722664. Pubmed Central PMCID: PMC1952921. Epub 1961/01/21. eng].
74. Thomas S.J.W.A., Von Herbay A., et al. How much agreement is there between histological, endoscopic, and clinical assessments of remission in ulcerative colitis. Gut 2009, 58(Suppl. 1):A101.
75. Binder V. A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa, and cytologic picture of mucosal exudate in ulcerative colitis. Scand J Gastroenterol 1970, 5(7):627-632. [PubMed PMID: 5474435. Epub 1970/01/01. eng].
76. Lemmens B., Arijs I., Van Assche G., et al. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis May 2013, 19(6):1194-1201. [PubMed PMID: 23518809. Epub 2013/03/23. eng].
77. Korelitz B.I., Sommers S.C. Response to drug therapy in Crohn's disease: evaluation by rectal biopsy and mucosal cell counts. J Clin Gastroenterol Apr 1984, 6(2):123-127. [PubMed PMID: 6143776. Epub 1984/04/01. eng].
78. Isaacs K.L. How rapidly should remission be achieved?. Dig Dis 2010, 28(3):548-555. [PubMed PMID: 20926885. Epub 2010/10/12. eng].
79. Lichtenstein G.R., Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis Feb 2010, 16(2):338-346. [PubMed PMID: 19637362. Epub 2009/07/29. eng].
80. Burger D.C.T.S., Walsh A.J., Von Herbay A., Buchell O.C., Keshav S., Warren B.F., et al. Depth of remission may not predict outcome of UC over 2years. J Crohns Colitis 2011, 5(S3):S4-S5.
81. Chey W.Y. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis May 2001, 7(Suppl. 1):S30-S33. [PubMed PMID: 11380041. Epub 2001/05/31. eng].
82. Green J.R., Mansfield J.C., Gibson J.A., et al. A double-blind comparison of balsalazide, 6.75g daily, and sulfasalazine, 3g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther Jan 2002, 16(1):61-68. [PubMed PMID: 11856079. Epub 2002/02/22. eng].
83. Gross V., Bar-Meir S., Lavy A., et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther Jan 15 2006, 23(2):303-312. [PubMed PMID: 16393311. Epub 2006/01/06. eng].
84. Kruis W., Kiudelis G., Racz I., et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut Feb 2009, 58(2):233-240. [PubMed PMID: 18832520. Pubmed Central PMCID: 3269751. Epub 2008/10/04. eng].
85. Lee F.I., Jewell D.P., Mani V., et al. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut Feb 1996, 38(2):229-233. [PubMed PMID: 8801202. Pubmed Central PMCID: 1383028. Epub 1996/02/01. eng].
86. Mansfield J.C., Giaffer M.H., Cann P.A., et al. A double-blind comparison of balsalazide, 6.75g, and sulfasalazine, 3g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther Jan 2002, 16(1):69-77. [PubMed PMID: 11856080. Epub 2002/02/22. eng].
87. Paoluzi O.A., Pica R., Marcheggiano A., et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther Oct 2002, 16(10):1751-1759. [PubMed PMID: 12269968. Epub 2002/09/25. eng].
88. Prantera C., Viscido A., Biancone L., et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis May 2005, 11(5):421-427. [PubMed PMID: 15867580. Epub 2005/05/04. eng].
89. Rao S.S., Dundas S.A., Holdsworth C.D., et al. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. Gut May 1989, 30(5):675-679. [PubMed PMID: 2567266. Pubmed Central PMCID: 1434223. Epub 1989/05/01. eng].
90. Ruddell W.S., Dickinson R.J., Dixon M.F., et al. Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone foam. Gut Oct 1980, 21(10):885-889. [PubMed PMID: 7002739. Pubmed Central PMCID: PMC1419374. Epub 1980/10/01. eng].
91. Sommers S.C., Korelitz B.I. Mucosal-cell counts in ulcerative and granulomatous colitis. Am J Clin Pathol Mar 1975, 63(3):359-365. [PubMed PMID: 234674. Epub 1975/03/01. eng].
92. Sherlock M.E., Seow C.H., Steinhart A.H., et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010, 10:CD007698. [PubMed PMID: 20927762. Epub 2010/10/12. eng].
93. Baert F.J., D'Haens G.R., Peeters M., et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology Jan 1999, 116(1):22-28. [PubMed PMID: 9869598. Epub 1998/12/31. eng].
94. Sandborn W.J., Travis S., Moro L., et al. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology Nov 2012, 143(5):1218-1226. [e1-2. PubMed PMID: 22892337. Epub 2012/08/16. eng].
95. Travis S.P., Danese S., Kupcinskas L., Travis S.P., Danese S., Kupcinskas L., et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014, 63(3):433-441. [PubMed PMID: 23436336. Epub 2013/02/26. Eng].
96. Baars J.E., Vogelaar L., Wolfhagen F.H., et al. A short course of corticosteroids prior to surveillance colonoscopy to decrease mucosal inflammation in inflammatory bowel disease patients: results from a randomized controlled trial. J Crohns Colitis Dec 2010, 4(6):661-668. [PubMed PMID: 21122577. Epub 2010/12/03. eng].
97. D'Haens G., Geboes K., Ponette E., et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology May 1997, 112(5):1475-1481. [PubMed PMID: 9136824. Epub 1997/05/01. eng].
98. D'Haens G., Geboes K., Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc Nov 1999, 50(5):667-671. [PubMed PMID: 10536324. Epub 1999/10/28. eng].
99. Kozarek R.A., Patterson D.J., Gelfand M.D., et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med Mar 1 1989, 110(5):353-356. [PubMed PMID: 2492786. Epub 1989/03/01. eng].
100. Mantzaris G.J., Christidou A., Sfakianakis M., et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis Mar 2009, 15(3):375-382. [PubMed PMID: 19009634. Epub 2008/11/15. eng].
101. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet May 4 2002, 359(9317):1541-1549. [PubMed PMID: 12047962. Epub 2002/06/06. eng].
102. Beattie R.M., Schiffrin E.J., Donnet-Hughes A., et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease. Aliment Pharmacol Ther Dec 1994, 8(6):609-615. [PubMed PMID: 7696450. Epub 1994/12/01. eng].
103. Borrelli O., Cordischi L., Cirulli M., et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol Jun 2006, 4(6):744-753. [PubMed PMID: 16682258. Epub 2006/05/10. eng].
104. Yamamoto T., Nakahigashi M., Umegae S., et al. Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflamm Bowel Dis Jun 2005, 11(6):580-588. [PubMed PMID: 15905706. Epub 2005/05/21. eng].
105. Bernstein C.N., Shanahan F., Anton P.A., et al. Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. Gastrointest Endosc Sep 1995, 42(3):232-237. [PubMed PMID: 7498688. Epub 1995/09/01. eng].
106. Kleer C.G., Appelman H.D. Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. Am J Surg Pathol Aug 1998, 22(8):983-989. [PubMed PMID: 9706978. Epub 1998/08/26. eng].
107. Geboes K., Dalle I. Influence of treatment on morphological features of mucosal inflammation. Gut May 2002, 50(Suppl. 3):III37-III42. [PubMed PMID: 11953331. Pubmed Central PMCID: 1867680. Epub 2002/04/16. eng].
108. Rubio C.A., Orrego A., Nesi G., et al. Frequency of epithelioid granulomas in colonoscopic biopsy specimens from paediatric and adult patients with Crohn's colitis. J Clin Pathol Nov 2007, 60(11):1268-1272. [PubMed PMID: 17293387. Pubmed Central PMCID: 2095463. Epub 2007/02/13. eng].
109. Schumacher G., Kollberg B., Sandstedt B. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Histologic course during the 1st year after presentation. Scand J Gastroenterol Apr 1994, 29(4):318-332.
110. Moum B., Ekbom A., Vatn M.H., et al. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol Jun 1999, 94(6):1564-1569. [PubMed PMID: 10364026. Epub 1999/06/11. eng].
111. Ferrante M., de Hertogh G., Hlavaty T., et al. The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence. Gastroenterology May 2006, 130(6):1595-1606. [PubMed PMID: 16697723. Epub 2006/05/16. eng].
112. Peyrin-Biroulet L., Cieza A., Sandborn W.J., et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut Feb 2012, 61(2):241-247. [PubMed PMID: 21646246. Pubmed Central PMCID: PMC3245899. Epub 2011/06/08. eng].
113. Pariente B., Cosnes J., Danese S., et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis Jun 2011, 17(6):1415-1422. [PubMed PMID: 21560202. Pubmed Central PMCID: PMC3116198. Epub 2011/05/12. eng].
114. Peyrin-Biroulet L., Billioud V., D'Haens G., et al. Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol Dec 2012, 107(12):1770-1776. [PubMed PMID: 23211844. Epub 2012/12/06. eng].
115. Smolen J.S., Aletaha D., Bijlsma J.W., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis Apr 2010, 69(4):631-637. [PubMed PMID: 20215140. Pubmed Central PMCID: PMC3015099. Epub 2010/03/11. eng].
116. Chamaillard M., Chevaux J.B., Peyrin-Biroulet L. Looking beyond histological healing in ulcerative colitis: towards the establishment of a molecular signature for quiescent but progressive disease. Gut Jul 2013, 62(7):959-960. [PubMed PMID: 23242120. Epub 2012/12/18. eng].
117. Planell N., Lozano J.J., Mora-Buch R., et al. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut Jul 2013, 62(7):967-976. [PubMed PMID: 23135761. Epub 2012/11/09. eng].
118. Arijs I., Li K., Toedter G., et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut Dec 2009, 58(12):1612-1619. [PubMed PMID: 19700435. Epub 2009/08/25. eng].
119. Buda A., Hatem G., Neumann H., et al. Confocal laser endomicroscopy for prediction of disease relapse in ulcerative colitis: A pilot study. J Crohns Colitis 2014, 8(4):304-311. [PubMed PMID: 24094597. Epub 2013/10/08. Eng].
120. Gheorghe C., Cotruta B., Iacob R., et al. Endomicroscopy for assessing mucosal healing in patients with ulcerative colitis. J Gastrointestin Liver Dis Dec 2011, 20(4):423-426. [PubMed PMID: 22187709. Epub 2011/12/22. eng].
121. Baron J.H., Connell A.M., Lennard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J Jan 11 1964, 1(5375):89-92. [PubMed PMID: 14075156. Pubmed Central PMCID: PMC1812908. Epub 1964/01/11. eng].